<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article249</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EINSTEIN-PE" style="display:block; margin-bottom:10px;">EINSTEIN-PE Original</a></li>
<h2><strong>EINSTEIN-PE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rivaroxaban versus Standard Therapy for Pulmonary Embolism Treatment". The New England Journal of Medicine. 2012. ClinicalTrials.gov number, NCT00439777.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does rivaroxaban, an oral factor Xa inhibitor, offer a safe and effective single-drug approach to the treatment of pulmonary embolism compared to standard therapy with enoxaparin followed by vitamin K antagonist?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Rivaroxaban provides similar protection from recurrent venous thromboembolism as standard therapy and may have an improved benefit-risk profile, offering a simplified approach to the treatment of pulmonary embolism.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff in 2023, there were no specific guidelines reflecting the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, open-label, event-driven, noninferiority trial<br/>
- N=4,832 patients with acute symptomatic pulmonary embolism<br/>
- Interventions:<br/>
    - Rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily)<br/>
    - Standard therapy (enoxaparin followed by adjusted-dose vitamin K antagonist)<br/>
- Duration: 3, 6, or 12 months<br/>
- Primary efficacy outcome: Symptomatic recurrent venous thromboembolism<br/>
- Principal safety outcome: Major or clinically relevant nonmajor bleeding<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Acute symptomatic pulmonary embolism with or without DVT<br/>
- Exclusion criteria: Thrombectomy, vena cava filter placement, fibrinolytic agents for the current episode, treatment with more than 48 hours of anticoagulation before randomization, contraindications to enoxaparin, warfarin, or acenocoumarol<br/>
- Baseline characteristics: Representative spectrum of patients presenting with symptomatic pulmonary embolism<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Rivaroxaban: 15 mg twice daily for 3 weeks, 20 mg once daily thereafter<br/>
- Standard therapy: Enoxaparin with transition to warfarin or acenocoumarol; discontinuing enoxaparin once INR of 2.0 or higher was maintained for 2 consecutive days.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome: Recurrent venous thromboembolism occurred in 50 patients (2.1%) in the rivaroxaban group and 44 patients (1.8%) in the standard therapy group (hazard ratio, 1.12; 95% CI, 0.75 to 1.68).<br/>
- Principal safety outcome: Clinically relevant bleeding occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07).<br/>
- Major bleeding: Observed in 1.1% in the rivaroxaban group vs. 2.2% in the standard therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79).<br/>
- Other outcomes: Acute coronary events and liver function abnormalities were low and similar between groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open-label design could introduce a diagnostic-suspicion bias.<br/>
- Brief exposure to low-molecular-weight heparin prior to randomization may affect outcomes, although it is a part of current clinical practice.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by Bayer HealthCare and Janssen Pharmaceuticals.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The complete study details and outcomes are available in The New England Journal of Medicine, 2012, and at the ClinicalTrials.gov database under the identifier NCT00439777.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
